BIOWIRE2K

ORLANDO, Fla.--(BW HealthWire)--June 3, 2002--At the American Society for Mass Spectrometry conference, Bruker Daltonics Inc. (NASDAQ: BDAL) today introduces AccuMass(TM), a new method for high mass accuracy protein identification on its esquire3000plus(TM) ion trap mass spectrometers. AccuMass improves both the mass accuracy of peptide mass fingerprints, and of MS/MS peptide sequence data acquired on esquire3000plus systems significantly, to 0.05 Daltons and better.

AccuMass allows the researcher to perform database searches with improved specificity due to better discrimination against false positives, while search times can be reduced fourfold. The combination of AccuMass with the superior scan power of the esquire3000plus, which resolves multiply-charged ions on-the-fly in standard scan mode at 13,000 amu/sec, makes the esquire3000plus the most powerful ion trap LC/MSn system for proteomics. For high-throughput environments, the esquire3000plus integrates into the Proteineer(TM) proteomics suite, combining automated sample preparation systems, mass spectrometry and bioinformatics.

ABOUT BRUKER DALTONICS

Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com.

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein.

--30--ch/bos*